The role and application of small extracellular vesicles in gastric cancer

Abstract

Gastric cancer (GC) is a common tumour that affects humans worldwide, is highly malignant and has a poor prognosis. Small extracellular vesicles (sEVs), especially exosomes, are nanoscale vesicles released by various cells that deliver bioactive molecules to recipient cells, affecting their biological characteristics, changing the tumour microenvironment and producing long-distance effects. In recent years, many studies have clarified the mechanisms by which sEVs function with regard to the initiation, progression, angiogenesis, metastasis and chemoresistance of GC. These molecules can function as mediators of cell-cell communication in the tumour microenvironment and might affect the efficacy of immunotherapy. Due to their unique physiochemical characteristics, sEVs show potential as effective antitumour vaccines as well as drug carriers. In this review, we summarize the roles of sEVs in GC and highlight the clinical application prospects in the future.

Introduction

As one of the most common malignant tumours, gastric cancer (GC) affects the physical and mental health of those at risk. In a report released by the International Agency for Research on Cancer, the worldwide incidence of GC ranks fifth among all tumours, and mortality ranks fourth [1]. Asia, especially East Asia, has a high incidence of GC. As patients with early GC typically have no symptoms, they often miss the opportunity for optimal treatment. With the advancement of endoscopy technology, an increasing number of GC cases are being diagnosed early, but the invasiveness and high cost of endoscopy restrict large-scale GC screening. At present, there is still a lack of noninvasive and highly accurate tumour biomarkers, which can strong support for the screening of GC, even in the early stages. Despite considerable recent progress in surgical treatment, endoscopic treatment, chemotherapy, radiotherapy, and targeted therapy, the prognosis of patients with advanced GC remains poor, causing a major burden on families and society. Therefore, the application of more indicators of risk and prognosis is urgently needed.

Small extracellular vesicles (sEVs), broadly present nanoscale vesicle structures secreted by almost all cells, can transmit information between cells and participate in their physiological and pathological processes. Due to their unique structural characteristics, sEVs have become hot research topics in recent years, and their role in the initiation and progression of GC is gradually being clarified.

A few years ago, two review articles [2, 3] gave a detailed summary of the role of extracellular vehicles (EVs) or exosomes in GC, which was important and caused an increase in exosome research in the field of GC. Currently, the structure, related technologies and mechanisms of exosomes are being discovered and applied. Most importantly, the International Society for Extracellular Vesicles issued guidelines at the end of 2018 to standardize the nomenclature of extracellular vesicles. Most methods used to isolate exosomes currently co-isolate heterogeneous populations of EVs of diverse biogenic origins. For accuracy and clarity, we refer to “sEVs”, typically called “exosomes” in publications, as small cell-derived membrane vesicles in accordance with the Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018) guidelines [4].

This review focused on emphasizing the major advancements in the past few years to reveal the role and application of sEVs in GC. A systematic literature search of Embase, PubMed, Web of Science, and Clinicaltrials.gov was performed for relevant publications up to 1 March 2021. MISEV 2018 guidelines were followed to screen literature about “Stomach Neoplasms”[Mesh], “Exosomes”[Mesh], and “small extracellular vesicles”.

The biological origin and structural characteristics of EVs

In 1983, John Stone et al. observed the process by which sheep reticulocytes transform into mature red blood cells and found that red blood cells release transferrin metabolites through some small vesicles, which were initially considered to be cell debris but were later confirmed to be separate structures and named exosomes [5]. Early endosomes are generated after inward budding of the plasma membrane and then transform into multivesicular bodies (MVBs) when membrane vesicles form by budding [6]. MVBs participate in the process of endocytosis and transport of intracellular materials, which involves the sorting, recovery, storage, transportation and release of proteins. MVBs are finally sent to the lysosome for degradation or fuse with the cell membrane and are released into the extracellular environment in a form called exosomes [7]. The most common hypothesis is that the endosomal sorting complex required for transport (ESCRT) family catalyses exosome budding [8]; however, there is no substantive decrease in exosome biogenesis after inhibition of ESCRT family activity [9]. In addition, ESCRT-independent mechanisms, such as heterogeneous nuclear ribonucleoprotein-dependent pathways and neutral sphingomyelinase 2-dependent pathways, were found to affect the formation of exosomes [10]. Recently, Kang et al. [11] identified a novel ESCRT-independent mechanism marked and controlled by RAB31, which has improved our understanding of exosome biogenesis (Fig. 1).

Exosomes are single-cell membrane vesicles with a lipid bilayer membrane structure, a size of approximately 30–150 nm and a density of approximately 1.13–1.21 g/ml [12]. Exosomes are derived from almost all human cells and are widely present in various body fluids, such as blood, urine, cerebrospinal fluid, tears, saliva, milk, ascites, lymph, and amniotic fluid [13].

Plasma membrane-derived ectosomes, also called microparticles or microvesicles, which are 100–1000 nm in diameter, may have largely analogous functions to exosomes [14]. Apoptotic bodies, also called apoptotic vesicles, can be observed when cells undergo apoptosis and may also be confused with other EVs [15].

The function of EVs mainly depends on their rich and complex cargo, of which approximately 76% comprises proteins and 15% mRNAs; the remaining components include DNAs, microRNAs (miRNAs), circular RNAs (circRNAs) and long noncoding RNAs (lncRNAs) [16–20].

However, without optimal separation strategies and specific markers of different sources of EVs at present, it is difficult to propose specific and universal markers of MVB-derived “exosomes” compared with other small EVs. The term “exosomes” was used to refer to EV preparations that have been separated from larger EVs, which refer to a mixture of sEVs of both exosomal and nonexosomal particles [21]. We used “small extracellular vesicles” (diameter < 200 or < 100 nm) in place of “exosomes” according to MISEV2018 [4].

Separation, characterization and storage of sEVs

A variety of protocols have been applied to the separation of sEVs [22, 23]. Differential ultracentrifugation is currently the most commonly used technique for sEV separation [24]. In addition, other classic techniques, such as density gradients [25], immunoisolation [26], precipitation [27] and filtration [28], are applied. Each method has advantages and disadvantages regarding recovery, specificity, time and cost [29, 30]. Although a number of novel techniques have been developed recently [31–34], absolute isolation of sEVs is still unrealistic, and combinations of methods will continue to be recommended.

Similarly, the identification of sEVs is complicated. Both the source of EVs and the EV preparation must be described quantitatively, according to MISEV2018. Protein content-based EV characteristics are routinely detected and analysed. Positive proteins must include at least one transmembrane/lipid-bound protein (usually CD9, CD63, CD83 and integrin) and one cytosolic protein recovered in EVs (usually ALIX, TSG101, syntenin and HSP70). The levels of at least one negative protein, such as albumin, lipoproteins, and ribosomal proteins, should also be determined. In addition, analysis of functional proteins, such as histones, cytochrome C, calnexin or Grp94, is required when claiming specific analysis of sEVs [4].

Western blotting is the most commonly used method and can detect both surface and internal proteins. Fluorescence microscopes can detect these structures labelled with specific fluorescent probes [35]. Flow cytometry can also be used but is restricted by the small size of sEVs and the low abundance of surface antigens [36]. Mass spectrometry has become economical and accessible in recent years [37]. However, a large number of sEVs are required for protein extraction, which reduces efficiency [6]. At least two different but complementary techniques are also recommended for characterization of the heterogeneity of single vesicles, such as transmission electron microscopy or atomic force microscopy [38].

The storage conditions of sEVs are also very important and may affect their characteristics. There is currently no general consensus that the original samples from which sEVs are extracted should be stored at − 80 °C and used as soon as possible when conducting experiments [39, 40].

The relationship between sEVs and GC

EVs play a relatively important role in the tumorigenesis of GC [41], and their effects on invasion, metastasis, angiogenesis, immune escape, and chemotherapy resistance have been confirmed by several studies (Fig. 2). In 2009, Qu et al. first reported that the sEVs of GC cells can at least partially promote tumour cell proliferation through the PI3K/Akt pathway and MAPK/ERK activation. Metabolism involving the Cbl ubiquitin ligase family and Caspases may also participate in this process [42, 43]. In 2012, Gu et al. confirmed that the TGF-β/Smad pathway mediated by sEVs triggers the differentiation of umbilical cord mesenchymal stem cells into cancer-related fibroblasts. CD97 is also thought to promote the proliferation and invasion of GC cells, and its ability to promote lymphatic metastasis in GC is related to sEVs [44, 45]. In addition, GC cell-derived sEVs can induce infiltration of peritoneal mesothelial cells (PMCs), and infiltrating PMCs in turn promote tumour subserosal invasion [46]. Overall, the interaction between cancer cells and PMCs accelerates gastric wall invasion and peritoneal metastasis. EVs also have an important role in the tumour microenvironment. For example, GC cell-derived sEVs stimulate the phosphorylation of NF-κB in macrophages to promote cancer progression [47] and induce the production of PD-1⁺ tumour-associated macrophages (TAMs), which is beneficial for tumour angiogenesis and metastasis [48]. A similar mechanism of action was reported by Shen et al. [49], and sEVs promote the polarization of N2 tumour-associated neutrophils to induce autophagy and increase tumour activation, promoting GC migration [50]. Ji et al. [51] and Wang et al. [52] revealed the role of sEVs in 5-Fluorouracil (5-FU) and platinum resistance. These studies contribute to the discovery and application of potential alternative drugs to reverse resistance.

Although the study of sEVs related to GC is still in early stages, the quantity and quality of related research have improved recently, providing new insight into the mechanisms underlying the initiation and progression of GC. In the following sections, we discuss the interaction between GC and sEV cargo in the tumour microenvironment and in GC cells to provide a comprehensive understanding of the relationship between them.

sEVs and GC initiation & progression

The initiation and progression of cancer are often affected by the mutual influence of tumour cells or the microenvironment, but the mechanism is not completely clear. Under physiological and pathological conditions, sEVs are released from the cell membrane, and the biologically active substances carried as cargo are involved in many processes (Table 1).

Although many studies have explored the relationship between sEVs and early gastric cancer, only a few articles have clarified the mechanism of sEVs in gastric carcinogenesis. Yoon et al. [55] identified Gastrokine 1 (GKN1) through a protein microarray in 2018 and found that it binds to 27 sEV proteins. GKN1 in sEVs can inhibit the proliferation of a variety of GC cells and induce apoptosis, and the results were supported in vitro. After further research, GKN1 was confirmed to be a tumour suppressor that reduces the initiation of GC by decreasing activation of the Hras/Raf/MEK/ERK signalling pathway, but its specificity is high, and the same effect has not been found in other gastrointestinal tumours [71]. Wei et al. [57] used qRT-PCR to show that miR-15b-3p is highly expressed in tissues, serum, cells and sEVs, enhancing the tumorigenesis and malignant transformation of GC by inhibiting the NYDLT1/Caspase-3/Caspase-9 pathway and suppressing apoptosis in GC. Based on these findings, it was proposed that miR-15b-3p can serve as a diagnostic and prognostic biomarker for GC. In addition, more articles have elucidated the mechanism of tumorigenesis through the exploration of the microenvironment, which we will describe later in the article.

Regarding the malignant behaviours of tumour cells, such as proliferation and invasion, many molecules have also been discovered. The FZD protein family of receptors in the Wnt signalling pathway plays an important role in gastrointestinal tumours. In cells with silencing of Frizzled 10 (FZD10) expression, addition of FZD10 and FZD10 mRNA restored viability. FZD10 has been shown to be a potential messenger of cancer reactivation and may play an equally active role in distant metastasis [53]. Mesenchymal stem cells (MSCs) are present in the tumour microenvironment. The N-recognin 2 (UBR2) component of ubiquitin protein ligase E3 can be delivered to target cells by sEVs to promote the growth and metastasis of GC [54]. Both GC tissue-induced mesenchymal stem cells [58] and bone marrow-induced mesenchymal stem cells [59] have been reported to significantly promote the growth and migration of GC cells through paracrine miR-221, the expression levels of which are closely related to lymphatic metastasis, venous infiltration and TNM staging. For instance, low expression of lncRNA SPRY4-IT1 caused dividing GC cells to stagnate in G1 phase, inhibiting the proliferation of GC cells. Overexpression of lncRNA SPRY4-IT1 promoted cell migration and invasion through the SPRY4-IT1/miR-101-3p/AMPK axis. SPRY4-IT1 has been shown to be transported in sEVs and is related to the progression and metastasis of GC [64].

Zhang et al. [68] detected an increased level of circNRIP1 expression in GC through RNA-seq analysis and showed that it has a tumour-promoting effect. Subsequently, the circNRIP1-miR-149-5p-AKT1/mTOR axis was found to be an important mechanism that promotes the proliferation, migration and invasion of GC, as determined by Western blot analysis and immunofluorescence. In addition, this molecule enhanced the stability of VEGF mRNA, as proven by in vivo and in vitro experiments. Moreover, circSHKBP1 can directly bind to HSP90 and hinder its interaction with STUB1, inhibiting the ubiquitination of HSP90 and promoting the proliferation, migration, invasion and angiogenesis of GC cells [69]. Recently, Zhang et al. showed that degradation of miR-30a or miR-30b could be induced by HOTAIR to promote the carcinogenesis of GC [72]. In addition, other cargo [60–62, 65–67, 70] plays a role in tumorigenesis and tumour progression.

Tumour cells develop significantly faster than vascular cells due to their strong proliferation, so hypoxia is often observed, and oxygen-monitoring mechanisms might be activated [73]. Xia et al. [63] found that hypoxia GC-derived sEV-enriched miR-301a-3p could target PHD3 to inhibit HIF-1α degradation. The sEV-miR-301a-3p/HIF-1α signalling axis facilitated GC proliferation and even metastasis.

Other studies have revealed that sEVs promote tumour progression through mechanisms such as the NF-κB pathway [47], Hedgehog pathway [74], and PI3K-Akt pathway [75]. Nonetheless, the contents of sEVs that play critical roles need to be further explored.

sEVs and angiogenesis & metastasis

Inhibiting gastric cancer-related angiogenesis is a current targeted treatment strategy for GC, and many studies involving coculture of GC cell sEVs with human umbilical vein endothelial cells (HUVESs) have been performed (Table 2). Studies have found that miR-130a [79], miR-135b [80], miR-155 [81, 82], miR-23a [83], X26nt [89] and YB-1 [76] promote angiogenesis through different mechanisms and proposed potential targets beyond conventional targeted drug therapy. A recently published article claimed that sEVs containing miR-6785-5p could suppress angiogenesis and metastasis in GC by inhibiting INHBA [84].

The premetastatic niche, a preformed microenvironment influenced by sEVs secreted from the primary site to distal metastasis, has been reviewed in many kinds of tumours [91–93]. Substantial in vitro and preclinical models have proven that sEV-driven transfer of biomolecular cargo between tumour and normal cells potently promotes distal microenvironments that are favourable to cancer growth [94]. A previous study demonstrated that integrin αvβ5 in sEVs was associated with liver metastasis [95]. In addition, sEVs containing secretory EGFR derived from GC cells effectively activate hepatocyte growth factor, which in turn binds to c-MET receptors on migrating cancer cells to promote the homing of metastatic cancer cells. Therefore, EGFR may be beneficial to the development of a liver-like microenvironment, leading to liver-specific metastasis [77]. Moreover, miR-196a-1 could promote metastasis to the liver in vitro and in vivo via sEVs from highly invasive to low-invasive GC cells [85]. Unfortunately, no more sEV-driven molecules that can indicate organ-specific metastasis have been discovered. We will describe the the relationship between sEVs and the microenvironment later in the article.

Peritoneal metastasis is a manifestation of advanced GC and often indicates a poor prognosis, and mesothelial cells function in the protective barrier of the peritoneum. EVs derived from GC can destroy the mesothelial barrier and cause peritoneal fibrosis, promoting peritoneal metastasis [96]. Similarly, miR-21-5p induced the mesothelial-to-mesenchymal transition (MMT) in peritoneal mesothelial cells and promoted peritoneal metastasis [87]. Using peritoneal lavage or ascites of patients with GC, Ohzawa et al. observed differences in the expression of miR-29 in patients with or without peritoneal metastasis; patients with low expression of miR-29b-3p had a higher peritoneal metastasis rate and a worse prognosis. MiR-29 may play an inhibitory role in the growth of diffuse peritoneal tumour cells [86].

Lymphatic metastasis is a common metastatic route of GC. Lu et al. studied the miR-877-3p/VEGFA axis mediated by circ-RanGAP1 and found that high expression of circ-RanGAP1 is closely related to TNM staging, lymphatic metastasis and poor survival [90]. A recently published study showed that bone marrow-derived mesenchymal stem cells could be specifically educated by sEVs containing Wnt5a via activation of the YAP signalling pathway [78]. This new insight into the mechanisms of lymphatic metastasis suggests potential therapeutic targets.

In addition, Piao et al. conducted a very interesting experiment in which they cocultured GC cells in conditioned medium from GC cells grown under hypoxia or normoxia and found that lncRNA PCGEM1 was highly expressed in GC cells cultured under hypoxic conditions and induced the invasion and metastasis of GC cells under normoxic conditions. This finding may be because PCGEM1 reduces the degradation of SNAI1, which in turn induces the epithelial-mesenchymal transition in GC; this finding may explain the molecular mechanism of GC cell invasion under hypoxic conditions [88]. Fu et al. discovered TRIM3 by screening the proteomic profile of serum sEVs in patients with GC and reported that it inhibits the growth and metastasis of GC in vitro and in vivo by regulating stem cell factors and EMT regulators [56].

sEVs and chemoresistance

Advanced unresectable GC usually involves comprehensive treatment based on drug therapy, commonly including chemotherapy and targeted therapy. However, in clinical practice, the same chemotherapy regimen often produces different therapeutic effects in different patients; some patients even develop chemotherapy resistance early, which is associated with poor prognosis and poses considerable therapeutic challenges. Many previous studies on the analysis of disease-related genes, combined with the molecular classification of GC, have been carried out to provide comprehensive treatment guidance for patients. With the development of sEV research in recent years, whether the contents of sEVs have an impact on chemotherapeutic resistance mechanisms and even the immune microenvironment has naturally become an emerging hot research topic [51]. sEVs might also have broad prospects for surmounting multidrug resistance in cancer [97] (Table 3).

Platinum drugs are one of the most common chemotherapy drugs used for GC, and cisplatin and oxaliplatin have been included as first-line treatments. Cisplatin-resistant gastric cancer cells communicate with sensitive cells through RPS3 in sEVs and activation of the PI3K-Akt-cofilin-1 signalling pathway [98]. Zheng et al. [99] found that M2-polarized macrophages can promote resistance to cisplatin in GC cells. sEV-miR-21 can be directly transferred from macrophages to GC cells, downregulating PTEN expressing and activating the PI3K/AKT signalling pathway to inhibit apoptosis. Moreover, a newly discovered form of iron-dependent oxidative cell death called ferroptosis is caused by lethal accumulation of lipid-based reactive oxygen species (ROS) [111], which may be related to tumour progression and drug resistance. Zhang et al. [100] found that arachidonic acid lipoxygenase 15 (ALOX15) is closely related to the production of lipid-based ROS in GC. The most valuable finding is that sEVs-miR-522 secreted by tumour-associated fibroblasts is a potential inhibitor of ALOX15, blocking the accumulation of lipid-based ROS and inhibiting ferroptosis in GC cells and thereby reducing sensitivity to chemotherapy drugs such as cisplatin and paclitaxel. Furthermore, miR-500a-3p and miR-214 are reportedly related to platinum resistance, and anti-miR-214 can reverse the resistance of GC to cisplatin. Perhaps in the near future, these molecules will become adjuvant drugs for the treatment of cisplatin-resistant GC [101–104]. A similar mechanism has also been reported for oxaliplatin resistance [105].

The drug 5-fluorouracil (5-FU) is another commonly used chemotherapy agent for GC. It has been reported [106] that hypermethylation of transcription factor activation promoter-binding protein 2e (TFAP2E) is related to 5-FU resistance. Highly expressed miR-106a-5p and miR-421 regulate the drug resistance induced by TFAP2E methylation, and bioinformatics analysis predicts that E2F1, MTOR and STAT3 may be target genes. Therefore, sEV- and miRNA-related mechanisms may be used to reverse drug resistance.

Additionally, sEVs may be involved in resistance to doxorubicin [107, 108], vincristine [109] and paclitaxel [110]. However, some data seem to be from cell research and it is speculated that they may be found in sEVs as they belong to a group of molecules which are frequently found in sEVs. Therefore, more rigorous and standardized experiments are needed for verification.

sEVs and the microenvironment & immunotherapy

EVs can also affect the tumour microenvironment, which mainly consists of inflammatory cells, stromal cells, extracellular matrix and so on (Table 4) (Fig. 3). Tumour-associated fibroblasts (CAFs) have a vital role in tumour progression. A recent study revealed that GOF p53-containing sEVs can promote fibroblast transformation into a tumour-associated phenotype [127]. Pericytes retain the characteristics of progenitor cells and differentiate into fibroblasts under pathological conditions. EVs derived from GC cells have been shown to enhance the proliferation and migration of pericytes and induce the expression of CAF markers. The above process is affected by BMP metastasis mediated by sEVs [112]. Helicobacter pylori is one of the most important pathogenic factors of antral GC, and CagA encoded by cytotoxin-related genes is the most critical toxin of this bacterium [128]. It has been reported that sEVs secreted by gastric epithelial cells expressing CagA may enter the circulation, deliver CagA to distant organs and tissues, and participate in the development of extragastric diseases related to cagA-positive H. pylori infection [113].

The main component of the tumour microenvironment, namely, tumour-associated macrophages (TAMs), has a tendency to promote cancer. Apolipoprotein E (Apo E) is a highly specific protein secreted by M2 macrophages. Apo E is expressed in the microenvironment of GC and activates the PI3K-Akt signalling pathway to promote metastasis [114]. H. pylori also activates MET and has a protumorigenic effect on TAMs [115]. However, the delivery of sEVs from TAMs contributes to cell proliferation [118]. M1 macrophage-derived sEVs containing miR-16-5p were found to trigger a T cell immune response by decreasing the expression of PD-L1, which could eventually suppress tumour progression [125].

Furthermore, sEVs affect the differentiation of T cells [116, 119] and promote transformation to carcinoma-associated fibroblasts [117, 120] and brown-like adipocytes [126]. By targeting Smad7 in peritoneal mesothelial cells, sEV-miR-106a plays a crucial role in GC peritoneal metastasis [121].

After coculture of tumour-associated fibroblasts with GC cells, the proliferation and invasion of the latter were inhibited, indicating that miRNA-34 may have tumour-suppressor effects, but the potential target genes and mechanisms need to be determined [122]. MiR-139, which is also derived from tumour-associated fibroblasts, can inhibit the progression and metastasis of GC by negatively regulating MMP11 [123].

In addition, bile acid might participate in the process of intestinal metaplasia and gastric epithelial cell proliferation [129], but the mechanism has not been fully elucidated. Xu et al. [124] demonstrated that DCA-activated macrophages could secrete sEVs to transport miR-30a-5 to GES-1 cells, thereby affecting the above process by targeting FOXD1. Then, tumour angiogenesis might be induced via the AKT/NF-κB pathway [130].

Finally, some studies have shown the influence of sEVs in the microenvironment, but specific substances have yet to be discovered, and further investigations are needed. Hinata et al. [131] reported that sEVs secreted by Epstein-Barr virus (EBV)-associated gastric cancer cells could suppress dendritic cell maturation, thereby negatively affecting the induction of tumour immunity. Liu et al. [132] showed that GC-derived sEVs could block the cell cycle and induce CD8⁺ T cell apoptosis. Lung metastasis could also be promoted due to the decrease in CD8⁺ T cells and NK cells and the increase in CD4⁺ T cells and myeloid-derived suppressor cells (MDSCs). Exosome-mediated metabolic reprogramming should also be further exploited to elucidate the mechanism of GC progression [133].

sEVs have strong potential in the field of cancer immunotherapy [134]. In clinical practice, with the development of PD-1/PD-L1-related research, immunotherapy-related clinical trials have gradually been carried out in patients with MSI-H and dMMR. Tumour immunotherapy has recently been a hot research topic, with a focus on clinical research related to programmed death receptor protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors, mainly for the activation and promotion of immune cells to counteract immune suppression and promote the killing effect against tumours [135]. Previous research has mainly focused on the role of soluble PD-L1, whereas there are few studies on sEV-PD-L1. Due to the secretory properties of sEVs, they can both inhibit and kill T cells in the local tumour microenvironment and be transferred to a remote site to exert other functions, which may be a powerful factor leading to tumour immune escape [136]. Fan et al. reported that due to its stability and T cell dysfunction caused by MHC-I expression, sEV-PD-L1 can reflect the immune status and predict the long-term prognosis of patients [137]. In addition, a study published in 2020 by Zhang et al. [138] stated that the use of 5-FU may upregulate the expression of sEV-PD-L1, which is likely to cause immunosuppression after more than two cycles of chemotherapy. This discovery may affect future comprehensive treatment strategies for advanced GC. It is also expected that further in-depth studies will clarify the relationship between different drug treatments and provide patients with accurate and efficient comprehensive treatment plans.

Most of the related literature has been published in the past three years, which may be due to the rapid development of proteomics and transcriptomics. With the continuous maturity of such technology, it is believed that more tumour-associated effects of sEV contents will be discovered. Of course, the proportion of tumour-associated cargo and the kind of effect sEVs produce under the action of multiple contents remain open questions.

Application prospects of sEVs in GC

Diagnosis and prognostic evaluation of GC

The lipid bilayer structure of sEVs protects their cargo from degradation while maintaining a fairly constant content. The noninvasive nature, possibility for real-time assessment and stable characteristics make sEVs an ideal potential biomarker [139, 140]. An sEVs-RNA-based test for early prostate cancer detection has been included in the National Comprehensive Cancer Network (NCCN) guidelines. Indeed, an increasing number of studies have proven that sEVs have strong developmental potential and application prospects in the early diagnosis and prognostic evaluation of GC (Table 5).

The earliest high-quality study was conducted by Zhou et al. [141] in 2015. Five highly expressed microRNAs were selected and assessed in the plasma of 30 GC patients and 30 healthy people, with verification in 71 and 61 and areas under the receiver operating characteristic (ROC) curve (AUC) of 0.86 and 0.74, respectively. In the subsequent external verification phase, the AUC was also as high, at 0.87. Unfortunately, a small number of patients do not show any increase in sEV microRNAs, and it may be necessary to further improve the selection of markers. In serum, high expression of membrane type 1 matrix metalloproteinase (MT1-MMP) is considered to be related to the tumour diameter, depth of invasion and TNM stage in GC. Moreover, the sEV-MT1-MMP axis has been proven to be an independent risk factor for GC lymphatic metastasis, which provides strong evidence for serological sEVs to predict the risk of lymphatic metastasis [142]. Huang et al. [143] adopted the Exiqon panel based on qRT-PCR and found 58 differentially expressed miRNAs using three GC sample banks and a normal control sample bank, and six miRNAs in serum (miR10b-5p, miR132-3p, miR185-5p, miR195-5p, miR-20a3p and miR296-5p) were selected for diagnosing GC. Other studies have also reported many new biomarkers [144–153].

In some studies, protein or DNA is the focus of sEVs detection. Yamamoto et al. [154] conducted methylation detection using sEVs derived from GC cell lines, GC tissues and gastric juice and found higher levels of BARHL2 methylation in gastric juice from early GC patients and GC cell lines, with lower levels in normal and atrophic gastritis. Moreover, after resection of early GC via endoscopy, the methylation level was significantly reduced. The AUC of this meaningful study was 0.923, and this approach is expected to become a highly accurate method for detecting early GC. For patients with metastatic GC, Ding et al. [169] provided a comprehensive description of the serum sEVs-proteome and found that several subunits might act as biomarkers and therapeutic targets.

In addition, lncRNAs and circRNAs have become important research molecules in recent years. In July 2020, a multistage study of 522 patients with GC, 85 patients with precancerous lesions of the stomach and 219 healthy people was published [155]. Subsequently, lncRNA-GC1 was found to be significantly elevated in GC cell culture medium, as confirmed in those with precancerous lesions and healthy people. As lncRNA-GC1 is almost exclusively secreted by sEVs, the level of lncRNA-GC1 can remain stable after ribonuclease treatment, even after prolonged exposure to room temperature or repeated freezing and thawing. Various studies have shown that this molecule is likely to become an ideal noninvasive GC diagnostic biomarker. In the future, the combination of lncRNA-GC1 detection and gastroscopy will substantially improve the early diagnosis rate of GC. Zhao et al. [145] analysed serological sEVs from 246 subjects and found that the expression level of HOTTIP in GC was high, with a higher diagnostic ability than CEA, CA 19–9 and CA72–4 (P < 0.001). Similarly, lncUEGC1 in sEVs has been confirmed to have a high sensitivity in the diagnosis of GC, which is expected to promote early GC screening in the future [159]. Other studies have contributed to the early diagnosis of GC [156–158].

Zhang et al. [160] used second-generation sequencing technology to obtain the RNA sequencing spectrum of GC patients for the first time and reported that miR-10b-5p, miR-101-3p and miR-143-5p could be used to distinguish lymphatic metastasis, ovarian metastasis and liver metastasis of GC. Such an early and accurate predictive method is conducive to the examination and evaluation of distant organs by clinicians as well as to the early detection of metastatic lesions, which is of practical value. By screening several microRNAs differentially expressed in GC patients and controls followed by further analysis and screening, researchers can use multiple microRNAs in combination for diagnosis and prognostic evaluation. From the perspective of GC ascites identification, Yun et al. used a microarray to detect the expression level of miRNAs in 73 cases of liver cirrhosis-related ascites and 92 cases of gastric cancer-related ascites and found that miR-181b-5p was superior to CEA in the diagnosis of GC ascites. When the two were used in combination, notable areas under the curve of 0.981 and 0.946 were achieved in the training and validation groups, respectively, revealing an excellent method of distinguishing the properties of ascites [161]. Kumata et al. [162] elaborated on the role of sEV-miRNAs in predicting the recurrence of GC: using miRNA chips, they found that miR-23b is specific for recurrence, and its ability to predict recurrence and prognosis at various tumour stages was fully demonstrated in 232 GC patients and 20 healthy volunteers.

Benefiting from their stable properties, sEV containing circRNAs have achieved remarkable results as biomarkers [158, 163–166]. CircRNA expression profile analysis of the plasma from GC patients at different TNM stages and healthy people showed lower circ-KIAA1244 in GC tissues, plasma and cell lines [163]. Through further clinical data analysis, it was found that decreased expression of circ-KIAA1244 correlated negatively with TNM staging and lymphatic metastasis, and the overall survival of such patients was significantly shortened. Subsequently, circ-0000419 was reported to be significantly related to tumour staging, distant metastasis, and venous and nerve infiltration. Both of them may become powerful indicators for early GC screening and prognostic evaluation of advanced GC. The risk of postoperative haematogenous metastasis of stage II/III GC [167] and peritoneal metastases [168] might also be predicted.

In ongoing clinical trials, sEVs are considered biomarkers of cancer diagnosis and prognosis. By monitoring changes in sEVs-HSP70 in the circulation, tumour response and clinical outcome could be predicted (NCT02662621 [170],). There are also two clinical trials focusing on the possibility of circulating sEVs as prognostic markers in advanced GC (NCT01779583) and digestive cancer (NCT04530890) without posted results.

Studies of sEVs as molecular markers are ongoing, and their biological characteristics contribute to the theoretical basis of clinical applications. Several websites have been developed to exhibit potential biomarkers for cancer diagnosis and prognosis [18, 171]. However, a literature review can reveal that early detection technology is dated and expensive, resulting in the small scale of the research to date [139]. As such, sample selection bias is impossible to avoid, which leads to uneven results. In recent years, with the government’s support for big-data platforms, the continuous upgrading of detection technologies and the gradual decline in detection costs, an increasing number of large-sample sequencing studies have been carried out to promote the implementation of sEV biomarkers in clinical practice.

Cancer drug delivery, antitumour vaccines and engineered sEVs

Efficient delivery and targeting of therapeutic cargo need be achieved to combat tumours, and sEVs can be used as drug delivery vehicles due to their unique physiochemical characteristics, high bioavailability and low nontargeted cytotoxicity [172].

Proton pump inhibitors (PPIs) are commonly used drugs to inhibit gastric acid secretion, and their antitumour potential is gradually being discovered. Guan et al. [173] found that high-dose PPIs can inhibit the release of sEVs and regulate the HIF-1α-FOXO1 axis, thereby regulating the tumour microenvironment and improving the prognosis of patients with advanced GC.

In the present literature, cancer cell-derived sEVs could preferentially fuse with their parent cancer cells [174]. Many sEVs have been used as carriers for antitumour proteins or microRNA inhibitors because of their tissue penetration, nonimmunogenicity, and cell tropism [175]. At present, only two clinical trials have explored the drug-carrying capacity of natural EVs, and they have not produced the expected results (NCT01294072 and NCT01854866). However, the number of patents based on EVs is still low; thus, further research is still warranted [176].

sEVs, especially exosomes, have now entered vaccine development [177, 178]. Numerous studies have shown that tumour-derived exosomes (TEXs) could have immunosuppressive effects as well as immunostimulatory effects [179–181]. Antitumour vaccines based on sEVs have been used to suppress tumour growth through dendritic cell-released MHC class I/peptide complexes for efficient CD8⁺ T cell priming [182]. Cheng et al. also demonstrated that sEVs derived from M1-polarized macrophages have the potential to be used as vaccine adjuvants due to their ability to home to lymph nodes and the expression of proinflammatory T helper cell type 1 cytokines [183]. For exploration of the feasibility of exosomes as immunotherapeutic vaccines, several clinical trials have been carried out or will be carried out (NCT01159288, NCT01550523 and NCT03608631). However, application of these treatments in GC is still progressing slowly.

Although natural EVs can elicit antitumour activities, there are still several problems. Accurate dose monitoring and targeted biodistribution in vivo are difficult to realize due to the high heterogeneity and complicated components of natural EVs, which lead to reduced therapeutic efficacy and safety concerns [184]. Therefore, artificial engineered sEVs have been generated through genetic and chemical methods to improve antitumour efficacy [185, 186].

Various strategies have been used for sEV engineering, of which loading target cargo or modification are two major strategies [187]. Cargo active loading into donor cells and direct loading into sEVs are the main components of the former [188]. In addition to constantly developing general modifications of EV membranes [189], new engineered EV-based platforms, such as EV-mimetic nanovesicles [190] and artificially synthesized EV-like synthetic nanoparticles [191], have gradually been developed.

There have been several animal models to investigate the utility of EVs for cancer drug delivery. For gastric cancer, sEVs containing anti-miR-214 could strengthen chemosensitivity and inhibit tumour growth in a cisplatin-resistant gastric cancer mouse model [52]. Pan et al. demonstrated that PMA/Au-BSA@Ce6 nanoparticles with deep penetration and superior retention performance could be used for cancer-targeted photodynamic therapy [192]. Genetically engineered K562-secreted sEVs containing HLA-A2 and several costimulatory molecules could activate CD8⁺ T cells to strengthen the effectiveness of immunotherapy [193]. Unfortunately, there is no research on sEVs in the chemotherapy of gastric cancer.

As shown above, although the application of sEVs has been extensively and profoundly explored in many cancers, further studies on this topic in gastric cancer are needed. We drew a compass-shaped diagram to show the role and application of sEVs in gastric cancer intuitively (Fig. 4). It is urgent to advance our understanding of sEVs to unlock their full potential in the prevention and treatment of gastric cancer. In addition, it also urgent to set up reliable assays to assess the therapeutic potential of sEVs, and to develop such assays into formal potency tests for cinical application [194].

Conclusion

Extensive attention has been paid to EVs in recent years. This research expands our understanding of the functions of sEVs and the mechanism of tumorigenesis and provides a new perspective for the prevention and treatment of gastric cancer. The mechanism of action of gastric cancer-related sEVs mainly depends on their complex cargo. In addition, communication between GC cells and the tumour microenvironment, as well as many unknown mechanisms and molecules, adds to the overall complexity and uncertainty.

Of course, opportunities and challenges coexist. The complicated cargo emphasizes the complexity of the mechanism, and the dominant roles of the various molecules and the mechanisms of the comprehensive effect are still unknown. Limited by immature technology, the diversity of detection methods and results, and the high cost of detection, few large-sample, multicentre studies have been conducted to date. Moreover, the genetic differences between East and West, between countries, and even between regions are likely to challenge the universality of existing research. Thus, prior to the clinical application of scientific results, there is an urgent need for further evaluation of the safety, effectiveness and stability of sEVs, and clinicians, pharmacists, and other professional scientists need to work together. Regardless, it is foreseeable that due to their unique biological characteristics, sEVs will become an important tool in the near future for accurate early diagnosis and personalized and efficient treatment of tumours, providing infinite power to overcome cancers.

Acknowledgements

AcknowledgementsThe authors apologize to the investigators and research laboratories whose original studies were not cited because of space limitations. Figures were created with BioRender.com and Adobe Illustrator.

Competing interests

Competing interestsThe authors declare that they have no competing interests.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021.10.3322/caac.2166033538338 doi:10.3322/caac.21660 PubMed
2. Fu M, Gu J, Jiang P, Qian H, Xu W, Zhang X. Exosomes in gastric cancer: roles, mechanisms, and applications. Mol Cancer. 2019 doi:10.1186/s12943-019-1001-7 PubMed
3. Huang T, Song C, Zheng L, Xia L, Li Y, Zhou Y. The roles of extracellular vesicles in gastric cancer development, microenvironment, anti-cancer drug resistance, and therapy. Mol Cancer. 2019 doi:10.1186/s12943-019-0967-5 PubMed
4. Thery C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018 doi:10.1080/20013078.2018.1535750 PubMed
5. Pan BT, Johnstone RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 1983 doi:10.1016/0092-8674(83)90040-5 PubMed
6. Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells. 2019;8:727.10.3390/cells8070727PMC667830231311206 doi:10.3390/cells8070727 PubMed
7. Borges FT, Reis LA, Schor N. Extracellular vesicles: structure, function, and potential clinical uses in renal diseases. Braz J Med Biol Res. 2013 doi:10.1590/1414-431X20132964 PubMed
8. Gould SJ, Booth AM, Hildreth JE. The Trojan exosome hypothesis. Proc Natl Acad Sci U S A. 2003 doi:10.1073/pnas.1831413100 PubMed
9. Fang Y, Wu N, Gan X, Yan W, Morrell JC, Gould SJ. Higher-order oligomerization targets plasma membrane proteins and HIV gag to exosomes. PLoS Biol. 2007 doi:10.1371/journal.pbio.0050158 PubMed
10. Tian X, Shen H, Li Z, Wang T, Wang S. Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment. J Hematol Oncol. 2019 doi:10.1186/s13045-019-0772-z PubMed
11. Wei D, Zhan W, Gao Y, Huang L, Gong R, Wang W, et al. RAB31 marks and controls an ESCRT-independent exosome pathway. Cell Res. 2020;31:157–77.10.1038/s41422-020-00409-1PMC802741132958903 doi:10.1038/s41422-020-00409-1 PubMed
12. Frydrychowicz M, Kolecka-Bednarczyk A, Madejczyk M, Yasar S, Dworacki G. Exosomes - structure, biogenesis and biological role in non-small-cell lung cancer. Scand J Immunol. 2015 doi:10.1111/sji.12247 PubMed
13. Pegtel DM, Gould SJ. Exosomes. Annu Rev Biochem. 2019 doi:10.1146/annurev-biochem-013118-111902 PubMed
14. Cocucci E, Meldolesi J. Ectosomes and exosomes: shedding the confusion between extracellular vesicles. Trends Cell Biol. 2015 doi:10.1016/j.tcb.2015.01.004 PubMed
15. Atkin-Smith GK, Tixeira R, Paone S, Mathivanan S, Collins C, Liem M et al. A novel mechanism of generating extracellular vesicles during apoptosis via a beads-on-a-string membrane structure. Nat Commun. 2015 doi:10.1038/ncomms8439 PubMed
16. Li Y, Zhao J, Yu S, Wang Z, He X, Su Y et al. Extracellular vesicles Long RNA sequencing reveals abundant mRNA, circRNA, and lncRNA in human blood as potential biomarkers for Cancer diagnosis. Clin Chem. 2019 doi:10.1373/clinchem.2018.301291 PubMed
17. Makarova J, Turchinovich A, Shkurnikov M, Tonevitsky A. Extracellular miRNAs and cell-cell communication: problems and prospects. Trends Biochem Sci. 2021.10.1016/j.tibs.2021.01.00733610425 doi:10.1016/j.tibs.2021.01.007 PubMed
18. Wang S, Zhang K, Tan S, Xin J, Yuan Q, Xu H et al. Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies. Mol Cancer. 2021 doi:10.1186/s12943-020-01298-z PubMed
19. Sun Z, Yang S, Zhou Q, Wang G, Song J, Li Z et al. Emerging role of exosome-derived long non-coding RNAs in tumor microenvironment. Mol Cancer. 2018 doi:10.1186/s12943-018-0831-z PubMed
20. Campos-Carrillo A, Weitzel JN, Sahoo P, Rockne R, Mokhnatkin JV, Murtaza M et al. Circulating tumor DNA as an early cancer detection tool. Pharmacol Ther. 2020 doi:10.1016/j.pharmthera.2019.107458 PubMed
21. Mathieu M, Martin-Jaular L, Lavieu G, Thery C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019 doi:10.1038/s41556-018-0250-9 PubMed
22. Monguio-Tortajada M, Galvez-Monton C, Bayes-Genis A, Roura S, Borras FE. Extracellular vesicle isolation methods: rising impact of size-exclusion chromatography. Cell Mol Life Sci. 2019 doi:10.1007/s00018-019-03071-y PubMed
23. Patel GK, Khan MA, Zubair H, Srivastava SK, Khushman M, Singh S et al. Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications. Sci Rep. 2019 doi:10.1038/s41598-019-41800-2 PubMed
24. Gardiner C, Di Vizio D, Sahoo S, Thery C, Witwer KW, Wauben M et al. Techniques used for the isolation and characterization of extracellular vesicles: results of a worldwide survey. J Extracell Vesicles. 2016 doi:10.3402/jev.v5.32945 PubMed
25. Lazaro-Ibanez E, Lasser C, Shelke GV, Crescitelli R, Jang SC, Cvjetkovic A et al. DNA analysis of low- and high-density fractions defines heterogeneous subpopulations of small extracellular vesicles based on their DNA cargo and topology. J Extracell Vesicles. 2019 doi:10.1080/20013078.2019.1656993 PubMed
26. He M, Crow J, Roth M, Zeng Y, Godwin AK. Integrated immunoisolation and protein analysis of circulating exosomes using microfluidic technology. Lab Chip. 2014 doi:10.1039/C4LC00662C PubMed
27. Li P, Kaslan M, Lee SH, Yao J, Gao Z. Progress in Exosome Isolation Techniques. Theranostics. 2017 doi:10.7150/thno.18133 PubMed
28. Kornilov R, Puhka M, Mannerstrom B, Hiidenmaa H, Peltoniemi H, Siljander P et al. Efficient ultrafiltration-based protocol to deplete extracellular vesicles from fetal bovine serum. J Extracell Vesicles. 2018 doi:10.1080/20013078.2017.1422674 PubMed
29. Dong L, Zieren RC, Horie K, Kim CJ, Mallick E, Jing Y et al. Comprehensive evaluation of methods for small extracellular vesicles separation from human plasma, urine and cell culture medium. J Extracell Vesicles. 2020 doi:10.1002/jev2.12044 PubMed
30. Yang D, Zhang W, Zhang H, Zhang F, Chen L, Ma L et al. Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics. Theranostics. 2020 doi:10.7150/thno.41580 PubMed
31. Crescitelli R, Lasser C, Lotvall J. Isolation and characterization of extracellular vesicle subpopulations from tissues. Nat Protoc. 2021;16:1548–80.10.1038/s41596-020-00466-133495626 doi:10.1038/s41596-020-00466-1 PubMed
32. Wu Y, Zhang N, Wu H, Sun N, Deng C. Magnetic porous carbon-dependent platform for the determination of N-glycans from urine exosomes. Mikrochim Acta. 2021 doi:10.1007/s00604-021-04728-x PubMed
33. Lin Q, Huang Z, Ye X, Yang B, Fang X, Liu B et al. Lab in a tube: isolation, extraction, and isothermal amplification detection of exosomal long noncoding RNA of gastric cancer. Talanta. 2021 doi:10.1016/j.talanta.2021.122090 PubMed
34. Yang HC, Ham YM, Kim JA, Rhee WJ. Single-step equipment-free extracellular vesicle concentration using super absorbent polymer beads. J Extracell Vesicles. 2021 doi:10.1002/jev2.12074 PubMed
35. Booth AM, Fang Y, Fallon JK, Yang JM, Hildreth JE, Gould SJ. Exosomes and HIV gag bud from endosome-like domains of the T cell plasma membrane. J Cell Biol. 2006 doi:10.1083/jcb.200508014 PubMed
36. Nolan JP, Duggan E. Analysis of individual extracellular vesicles by flow Cytometry. Methods Mol Biol. 1678 doi:10.1007/978-1-4939-7346-0_5 PubMed
37. Shao H, Im H, Castro CM, Breakefield X, Weissleder R, Lee H. New Technologies for Analysis of extracellular vesicles. Chem Rev. 2018 doi:10.1021/acs.chemrev.7b00534 PubMed
38. Witwer KW, Soekmadji C, Hill AF, Wauben MH, Buzas EI, Di Vizio D et al. Updating the MISEV minimal requirements for extracellular vesicle studies: building bridges to reproducibility. J Extracell Vesicles. 2017 doi:10.1080/20013078.2017.1396823 PubMed
39. Mendt M, Kamerkar S, Sugimoto H, McAndrews KM, Wu CC, Gagea M, et al. Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight. 2018;3:e99263.10.1172/jci.insight.99263PMC593113129669940 doi:10.1172/jci.insight.99263 PubMed
40. Maroto R, Zhao Y, Jamaluddin M, Popov VL, Wang H, Kalubowilage M et al. Effects of storage temperature on airway exosome integrity for diagnostic and functional analyses. J Extracell Vesicles. 2017 doi:10.1080/20013078.2017.1359478 PubMed
41. Mashouri L, Yousefi H, Aref AR, Ahadi AM, Molaei F, Alahari SK. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer. 2019 doi:10.1186/s12943-019-0991-5 PubMed
42. Qu JL, Qu XJ, Qu JL, Qu XJ, Zhao MF, Teng YE et al. The role of cbl family of ubiquitin ligases in gastric cancer exosome-induced apoptosis of Jurkat T cells. Acta Oncol. 2009 doi:10.3109/02841860903032817 PubMed
43. Qu JL, Qu XJ, Zhao MF, Teng YE, Zhang Y, Hou KZ et al. Gastric cancer exosomes promote tumour cell proliferation through PI3K/Akt and MAPK/ERK activation. Dig Liver Dis. 2009 doi:10.1016/j.dld.2009.04.006 PubMed
44. Liu D, Li C, Trojanowicz B, Li X, Shi D, Zhan C et al. CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent. Gastric Cancer. 2016 doi:10.1007/s10120-015-0523-y PubMed
45. Li C, Liu DR, Li GG, Wang HH, Li XW, Zhang W et al. CD97 promotes gastric cancer cell proliferation and invasion through exosome-mediated MAPK signaling pathway. World J Gastroenterol. 2015 doi:10.3748/wjg.v21.i20.6215 PubMed
46. Tanaka M, Kuriyama S, Itoh G, Maeda D, Goto A, Tamiya Y et al. Mesothelial cells create a novel tissue niche that facilitates gastric Cancer invasion. Cancer Res. 2017 doi:10.1158/0008-5472.CAN-16-0964 PubMed
47. Wu L, Zhang X, Zhang B, Shi H, Yuan X, Sun Y et al. Exosomes derived from gastric cancer cells activate NF-kappaB pathway in macrophages to promote cancer progression. Tumour Biol. 2016 doi:10.1007/s13277-016-5071-5 PubMed
48. Wang F, Li B, Wei Y, Zhao Y, Wang L, Zhang P et al. Tumor-derived exosomes induce PD1(+) macrophage population in human gastric cancer that promotes disease progression. Oncogenesis. 2018 doi:10.1038/s41389-018-0049-3 PubMed
49. Shen Y, Xue C, Li X, Ba L, Gu J, Sun Z et al. Effects of gastric Cancer cell-derived Exosomes on the immune regulation of Mesenchymal stem cells by the NF-kB signaling pathway. Stem Cells Dev. 2019 doi:10.1089/scd.2018.0125 PubMed
50. Zhang X, Shi H, Yuan X, Jiang P, Qian H, Xu W. Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration. Mol Cancer. 2018 doi:10.1186/s12943-018-0898-6 PubMed
51. Ji R, Zhang B, Zhang X, Xue J, Yuan X, Yan Y et al. Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer. Cell Cycle. 2015 doi:10.1080/15384101.2015.1005530 PubMed
52. Wang X, Zhang H, Bai M, Ning T, Ge S, Deng T et al. Exosomes serve as nanoparticles to deliver anti-miR-214 to reverse Chemoresistance to Cisplatin in gastric Cancer. Mol Ther. 2018 doi:10.1016/j.ymthe.2018.01.001 PubMed
53. Scavo MP, Depalo N, Rizzi F, Ingrosso C, Fanizza E, Chieti A, et al. FZD10 carried by Exosomes sustains Cancer cell proliferation. Cells. 2019;8:777.10.3390/cells8080777PMC672157631349740 doi:10.3390/cells8080777 PubMed
54. Mao J, Liang Z, Zhang B, Yang H, Li X, Fu H et al. UBR2 enriched in p53 deficient mouse bone marrow Mesenchymal stem cell-exosome promoted gastric Cancer progression via Wnt/beta-catenin pathway. Stem Cells. 2017 doi:10.1002/stem.2702 PubMed
55. Yoon JH, Ham IH, Kim O, Ashktorab H, Smoot DT, Nam SW et al. Gastrokine 1 protein is a potential theragnostic target for gastric cancer. Gastric Cancer. 2018 doi:10.1007/s10120-018-0828-8 PubMed
56. Fu H, Yang H, Zhang X, Wang B, Mao J, Li X et al. Exosomal TRIM3 is a novel marker and therapy target for gastric cancer. J Exp Clin Cancer Res. 2018 doi:10.1186/s13046-018-0825-0 PubMed
57. Wei S, Peng L, Yang J, Sang H, Jin D, Li X et al. Exosomal transfer of miR-15b-3p enhances tumorigenesis and malignant transformation through the DYNLT1/Caspase-3/Caspase-9 signaling pathway in gastric cancer. J Exp Clin Cancer Res. 2020 doi:10.1186/s13046-019-1511-6 PubMed
58. Wang M, Zhao C, Shi H, Zhang B, Zhang L, Zhang X et al. Deregulated microRNAs in gastric cancer tissue-derived mesenchymal stem cells: novel biomarkers and a mechanism for gastric cancer. Br J Cancer. 2014 doi:10.1038/bjc.2014.14 PubMed
59. Ma M, Chen S, Liu Z, Xie H, Deng H, Shang S et al. Zuo C: miRNA-221 of exosomes originating from bone marrow mesenchymal stem cells promotes oncogenic activity in gastric cancer. Onco Targets Ther. 2017 doi:10.2147/OTT.S143315 PubMed
60. Huang J, Shen M, Yan M, Cui Y, Gao Z, Meng X. Exosome-mediated transfer of miR-1290 promotes cell proliferation and invasion in gastric cancer via NKD1. Acta Biochim Biophys Sin Shanghai. 2019 doi:10.1093/abbs/gmz077 PubMed
61. Yang H, Fu H, Wang B, Zhang X, Mao J, Li X et al. Exosomal miR-423-5p targets SUFU to promote cancer growth and metastasis and serves as a novel marker for gastric cancer. Mol Carcinog. 2018 doi:10.1002/mc.22838 PubMed
62. Shi SS, Zhang HP, Yang CQ, Li LN, Shen Y, Zhang YQ. Exosomal miR-155-5p promotes proliferation and migration of gastric cancer cells by inhibiting TP53INP1 expression. Pathol Res Pract. 2020 doi:10.1016/j.prp.2020.152986 PubMed
63. Xia X, Wang S, Ni B, Xing S, Cao H, Zhang Z et al. Hypoxic gastric cancer-derived exosomes promote progression and metastasis via MiR-301a-3p/PHD3/HIF-1 ¦Á positive feedback loop. Oncogene. 2020 doi:10.1038/s41388-020-01425-6 PubMed
64. Cao S, Lin L, Xia X. Wu H: lncRNA SPRY4-IT1 regulates cell proliferation and migration by sponging miR-101-3p and regulating AMPK expression in gastric Cancer. Mol Ther Nucleic Acids. 2019 doi:10.1016/j.omtn.2019.04.030 PubMed
65. Pan L, Liang W, Fu M, Huang ZH, Li X, Zhang W et al. Exosomes-mediated transfer of long noncoding RNA ZFAS1 promotes gastric cancer progression. J Cancer Res Clin Oncol. 2017 doi:10.1007/s00432-017-2361-2 PubMed
66. Lu Y, Hou K, Li M, Wu X, Yuan S. Exosome-delivered LncHEIH promotes gastric Cancer progression by Upregulating EZH2 and stimulating me thylation of the GSDME promoter. Front Cell Dev Biol. 2020 doi:10.3389/fcell.2020.571297 PubMed
67. Wang L, Bo X, Yi X, Xiao X, Zheng Q, Ma L et al. Exosome-transferred LINC01559 promotes the progression of gastric cancer via PI3K/AKT signaling pathw ay. Cell Death Dis. 2020 doi:10.1038/s41419-020-02810-5 PubMed
68. Zhang X, Wang S, Wang H, Cao J, Huang X, Chen Z et al. Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway. Mol Cancer. 2019 doi:10.1186/s12943-018-0935-5 PubMed
69. Xie M, Yu T, Jing X, Ma L, Fan Y, Yang F et al. Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation. Mol Cancer. 2020 doi:10.1186/s12943-020-01208-3 PubMed
70. Hui C, Tian L, He X. Circular RNA circNHSL1 contributes to gastric Cancer progression through the miR-149-5p/YWHAZ Axis. Cancer Manag Res. 2020 doi:10.2147/CMAR.S253152 PubMed
71. Yoon JH, Ashktorab H, Smoot DT, Nam SW, Hur H, Park WS. Uptake and tumor-suppressive pathways of exosome-associated GKN1 protein in gastric epithelial cells. Gastric Cancer. 2020 doi:10.1007/s10120-020-01068-2 PubMed
72. Zhang J, Qiu WQ, Zhu H, Liu H, Sun JH, Chen Y et al. HOTAIR contributes to the carcinogenesis of gastric cancer via modulating cellular and exosomal miRNA s level. Cell Death Dis. 2020 doi:10.1038/s41419-020-02946-4 PubMed
73. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med (Berl). 2007 doi:10.1007/s00109-007-0281-3 PubMed
74. Qi J, Zhou Y, Jiao Z, Wang X, Zhao Y, Li Y et al. Exosomes derived from human bone marrow Mesenchymal stem cells promote tumor growth through hedgehog signaling pathway. Cell Physiol Biochem. 2017 doi:10.1159/000479998 PubMed
75. Gu H, Ji R, Zhang X, Wang M, Zhu W, Qian H et al. Exosomes derived from human mesenchymal stem cells promote gastric cancer cell growth and migration via the activation of the Akt pathway. Mol Med Rep. 2016 doi:10.3892/mmr.2016.5625 PubMed
76. Xue X, Huang J, Yu K, Chen X, He Y, Qi D et al. YB-1 transferred by gastric cancer exosomes promotes angiogenesis via enhancing the expression of ang iogenic factors in vascular endothelial cells. BMC Cancer. 2020 doi:10.1186/s12885-020-07509-6 PubMed
77. Zhang H, Deng T, Liu R, Bai M, Zhou L, Wang X et al. Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. Nat Commun. 2017 doi:10.1038/ncomms15016 PubMed
78. Wang M, Zhao X, Qiu R, Gong Z, Huang F, Yu W, et al. Lymph node metastasis-derived gastric cancer cells educate bone marrow-derived mesenchymal stem cells via YAP signaling activation by exosomal Wnt5a. Oncogene. 2021;40:2296–308.10.1038/s41388-021-01722-8PMC799420133654199 doi:10.1038/s41388-021-01722-8 PubMed
79. Yang H, Zhang H, Ge S, Ning T, Bai M, Li J et al. Exosome-derived miR-130a activates angiogenesis in gastric Cancer by targeting C-MYB in vascular endothelial cells. Mol Ther. 2018 doi:10.1016/j.ymthe.2018.07.023 PubMed
80. Bai M, Li J, Yang H, Zhang H, Zhou Z, Deng T et al. Ba Y: miR-135b delivered by gastric tumor Exosomes inhibits FOXO1 expression in endothelial cells and promotes angiogenesis. Mol Ther. 2019 doi:10.1016/j.ymthe.2019.06.018 PubMed
81. Deng T, Zhang H, Yang H, Wang H, Bai M, Sun W et al. Exosome miR-155 derived from gastric carcinoma promotes angiogenesis by targeting the c-MYB/VEGF Axis of endothelial cells. Mol Ther Nucleic Acids. 2020 doi:10.1016/j.omtn.2020.01.024 PubMed
82. Zhou Z, Zhang H, Deng T, Ning T, Liu R, Liu D et al. Exosomes carrying MicroRNA-155 target Forkhead box O3 of endothelial cells and promote angiogenesis in gastric Cancer. Mol Ther Oncolytics. 2019 doi:10.1016/j.omto.2019.10.006 PubMed
83. Du J, Liang Y, Li J, Zhao JM, Wang ZN, Lin XY. Gastric Cancer cell-derived Exosomal microRNA-23a promotes angiogenesis by targeting PTEN. Front Oncol. 2020 doi:10.3389/fonc.2020.00326 PubMed
84. Chen Z, Xie Y, Chen W, Li T, Chen X. Liu B: microRNA-6785-5p-loaded human umbilical cord mesenchymal stem cells-derived exosomes suppress angiogenesis and metastasis in gastric cancer via INHBA. Life Sci. 2021:119222.10.1016/j.lfs.2021.11922233609542 doi:10.1016/j.lfs.2021.119222 PubMed
85. Feng C, She J, Chen X, Zhang Q, Zhang X, Wang Y et al. Exosomal miR-196a-1 promotes gastric cancer cell invasion and metastasis by targeting SFRP1. Nanomedicine (London). 2019 doi:10.2217/nnm-2019-0053 PubMed
86. Ohzawa H, Saito A, Kumagai Y, Kimura Y, Yamaguchi H, Hosoya Y et al. Reduced expression of exosomal miR29s in peritoneal fluid is a useful predictor of peritoneal recurrence after curative resection of gastric cancer with serosal involvement. Oncol Rep. 2020 doi:10.3892/or.2020.7505 PubMed
87. Li Q, Li B, Li Q, Wei S, He Z, Huang X et al. Exosomal miR-21-5p derived from gastric cancer promotes peritoneal metastasis via mesothelial-to-mesenchymal transition. Cell Death Dis. 2018 doi:10.1038/s41419-018-0928-8 PubMed
88. Piao HY, Guo S, Wang Y, Zhang J. Exosome-transmitted lncRNA PCGEM1 promotes invasive and metastasis in gastric cancer by maintaining the stability of SNAI1. Clin Transl Oncol. 2021;23:246–56.10.1007/s12094-020-02412-932519176 doi:10.1007/s12094-020-02412-9 PubMed
89. Chen X, Zhang S, Du K, Zheng N, Liu Y, Chen H, et al. Gastric Cancer-secreted Exosomal X26nt increases angiogenesis and vascular permeability by targeting VE-cadherin. Cancer Sci. 2020.10.1111/cas.14740PMC808895433205567 doi:10.1111/cas.14740 PubMed
90. Lu J, Wang YH, Yoon C, Huang XY, Xu Y, Xie JW et al. Circular RNA circ-RanGAP1 regulates VEGFA expression by targeting miR-877-3p to facilitate gastric cancer invasion and metastasis. Cancer Lett. 2020 doi:10.1016/j.canlet.2019.11.038 PubMed
91. Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015 doi:10.1038/ncb3169 PubMed
92. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012 doi:10.1038/nm.2753 PubMed
93. Feng W, Dean DC, Hornicek FJ, Shi H, Duan Z. Exosomes promote pre-metastatic niche formation in ovarian cancer. Mol Cancer. 2019 doi:10.1186/s12943-019-1049-4 PubMed
94. Moller A, Lobb RJ. The evolving translational potential of small extracellular vesicles in cancer. Nat Rev Cancer. 2020 doi:10.1038/s41568-020-00299-w PubMed
95. Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015 doi:10.1038/nature15756 PubMed
96. Deng G, Qu J, Zhang Y, Che X, Cheng Y, Fan Y et al. Gastric cancer-derived exosomes promote peritoneal metastasis by destroying the mesothelial barrier. FEBS Lett. 2017 doi:10.1002/1873-3468.12722 PubMed
97. Lepeltier E, Rijo P, Rizzolio F, Popovtzer R, Petrikaite V, Assaraf YG et al. Nanomedicine to target multidrug resistant tumors. Drug Resist Updat. 2020 doi:10.1016/j.drup.2020.100704 PubMed
98. Sun MY, Xu B, Wu QX, Chen WL, Cai S, Zhang H et al. Cisplatin-resistant gastric Cancer cells promote the Chemoresistance of Cisplatin-sensitive cells via the Exosomal RPS3-mediated PI3K-Akt-Cofilin-1 signaling Axis. Front Cell Dev Biol. 2021 doi:10.3389/fcell.2021.618899 PubMed
99. Zheng P, Chen L, Yuan X, Luo Q, Liu Y, Xie G et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res. 2017 doi:10.1186/s13046-017-0528-y PubMed
100. Zhang H, Deng T, Liu R, Ning T, Yang H, Liu D et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020 doi:10.1186/s12943-020-01168-8 PubMed
101. Lin H, Zhang L, Zhang C, Liu P. Exosomal MiR-500a-3p promotes cisplatin resistance and stemness via negatively regulating FBXW7 in gastric cancer. J Cell Mol Med. 2020;24:8930–41.10.1111/jcmm.15524PMC741771332588541 doi:10.1111/jcmm.15524 PubMed
102. Wang J, Lv B, Su Y, Wang X, Bu J, Yao L. Exosome-mediated transfer of lncRNA HOTTIP promotes Cisplatin resistance in gastric Cancer cells by regulating HMGA1/miR-218 Axis. Onco Targets Ther. 2019 doi:10.2147/OTT.S231846 PubMed
103. Liu S, Wu M, Peng M. Circ_0000260 regulates the development and deterioration of gastric adenocarcinoma with Cisplatin res istance by Upregulating MMP11 via targeting MiR-129-5p. Cancer Manag Res. 2020 doi:10.2147/CMAR.S272324 PubMed
104. Yao W, Guo P, Mu Q, Wang Y. Exosome-derived Circ-PVT1 contributes to Cisplatin resistance by regulating autophagy, invasion, and apoptosis via miR-30a-5p/YAP1 Axis in gastric Cancer cells. Cancer Biother Radiopharm. 2020.10.1089/cbr.2020.357832799541 doi:10.1089/cbr.2020.3578 PubMed
105. Zhong Y, Wang D, Ding Y, Tian G, Jiang B. Circular RNA circ_0032821 contributes to oxaliplatin (OXA) resistance of gastric cancer cells by regulating SOX9 via miR-515-5p. Biotechnol Lett. 2020;43:339–51.10.1007/s10529-020-03036-333123829 doi:10.1007/s10529-020-03036-3 PubMed
106. Jingyue S, Xiao W, Juanmin Z, Wei L, Daoming L, Hong X. TFAP2E methylation promotes 5fluorouracil resistance via exosomal miR106a5p and miR421 in gastric cancer MGC803 cells. Mol Med Rep. 2019 doi:10.3892/mmr.2019.10237 PubMed
107. Liu X, Lu Y, Xu Y, Hou S, Huang J, Wang B et al. Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer. Cancer Lett. 2019 doi:10.1016/j.canlet.2019.05.035 PubMed
108. Gao H, Ma J, Cheng Y, Zheng P. Exosomal transfer of macrophage-derived miR-223 confers doxorubicin resistance in gastric Cancer. Onco Targets Ther. 2020 doi:10.2147/OTT.S283542 PubMed
109. Zhao K, Wang Z, Li X, Liu JL, Tian L, Chen JQ. Exosome-mediated transfer of CLIC1 contributes to the vincristine-resistance in gastric cancer. Mol Cell Biochem. 2019 doi:10.1007/s11010-019-03613-9 PubMed
110. Wang M, Qiu R, Yu S, Xu X, Li G, Gu R et al. Paclitaxelresistant gastric cancer MGC803 cells promote epithelialtomesenchymal transition and chemoresistance in paclitaxelsensitive cells via exosomal delivery of miR1555p. Int J Oncol. 2019 doi:10.3892/ijo.2018.4601 PubMed
111. Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ et al. Ferroptosis: a regulated cell death Nexus linking metabolism, redox biology, and disease. Cell. 2017 doi:10.1016/j.cell.2017.09.021 PubMed
112. Ning X, Zhang H, Wang C, Song X. Exosomes released by gastric Cancer cells induce transition of Pericytes into Cancer-associated fibroblasts. Med Sci Monit. 2018 doi:10.12659/MSM.906641 PubMed
113. Shimoda A, Ueda K, Nishiumi S, Murata-Kamiya N, Mukai SA, Sawada S et al. Exosomes as nanocarriers for systemic delivery of the helicobacter pylori virulence factor CagA. Sci Rep. 2016 doi:10.1038/srep18346 PubMed
114. Zheng P, Luo Q, Wang W, Li J, Wang T, Wang P et al. Tumor-associated macrophages-derived exosomes promote the migration of gastric cancer cells by transfer of functional Apolipoprotein E. Cell Death Dis. 2018 doi:10.1038/s41419-018-0465-5 PubMed
115. Che Y, Geng B, Xu Y, Miao X, Chen L, Mu X et al. Helicobacter pylori-induced exosomal MET educates tumour-associated macrophages to promote gastric cancer progression. J Cell Mol Med. 2018 doi:10.1111/jcmm.13847 PubMed
116. Yen EY, Miaw SC, Yu JS, Lai IR. Exosomal TGF-beta1 is correlated with lymphatic metastasis of gastric cancers. Am J Cancer Res. 2017 PubMed
117. Gu J, Qian H, Shen L, Zhang X, Zhu W, Huang L et al. Gastric cancer exosomes trigger differentiation of umbilical cord derived mesenchymal stem cells to carcinoma-associated fibroblasts through TGF-beta/Smad pathway. PLoS One. 2012 doi:10.1371/journal.pone.0052465 PubMed
118. Wang JJ, Wang ZY, Chen R, Xiong J, Yao YL, Wu JH et al. Macrophage-secreted Exosomes delivering miRNA-21 inhibitor can regulate BGC-823 cell proliferation. Asian Pac J Cancer Prev. 2015 doi:10.7314/APJCP.2015.16.10.4203 PubMed
119. Liu F, Bu Z, Zhao F, Xiao D. Increased T-helper 17 cell differentiation mediated by exosome-mediated microRNA-451 redistribution in gastric cancer infiltrated T cells. Cancer Sci. 2018 doi:10.1111/cas.13429 PubMed
120. Wang J, Guan X, Zhang Y, Ge S, Zhang L, Li H et al. Exosomal miR-27a derived from gastric Cancer cells regulates the transformation of fibroblasts into Cancer-associated fibroblasts. Cell Physiol Biochem. 2018 doi:10.1159/000493218 PubMed
121. Zhu M, Zhang N, He S, Lu X. Exosomal miR-106a derived from gastric cancer promotes peritoneal metastasis via direct regulation of Smad7. Cell Cycle. 2020 doi:10.1080/15384101.2020.1749467 PubMed
122. Shi L, Wang Z, Geng X, Zhang Y, Xue Z. Exosomal miRNA-34 from cancer-associated fibroblasts inhibits growth and invasion of gastric cancer cells in vitro and in vivo. Aging (Albany NY). 2020 doi:10.18632/aging.103157 PubMed
123. Xu G, Zhang B, Ye J, Cao S, Shi J, Zhao Y et al. Exosomal miRNA-139 in cancer-associated fibroblasts inhibits gastric cancer progression by repressing MMP11 expression. Int J Biol Sci. 2019 doi:10.7150/ijbs.33750 PubMed
124. Xu X, Cheng J, Luo S, Huang D, Xu J, Qian Y et al. Deoxycholic acid-stimulated macrophage-derived exosomes promote intestinal metaplasia and suppress pr oliferation in human gastric epithelial cells. Eur J Pharmacol. 2020 doi:10.1016/j.ejphar.2020.173566 PubMed
125. Li Z, Suo B, Long G, Gao Y, Song J, Zhang M et al. Exosomal miRNA-16-5p derived from M1 macrophages enhances T cell-dependent immune response by regulating PD-L1 in gastric Cancer. Front Cell Dev Biol. 2020 doi:10.3389/fcell.2020.572689 PubMed
126. Zhang H, Zhu L, Bai M, Liu Y, Zhan Y, Deng T et al. Exosomal circRNA derived from gastric tumor promotes white adipose browning by targeting the miR-133/PRDM16 pathway. Int J Cancer. 2019 doi:10.1002/ijc.31977 PubMed
127. Ma S, McGuire MH, Mangala LS, Lee S, Stur E, Hu W et al. Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. Cell Rep. 2021 doi:10.1016/j.celrep.2021.108726 PubMed
128. Hatakeyama M. Oncogenic mechanisms of the helicobacter pylori CagA protein. Nat Rev Cancer. 2004 doi:10.1038/nrc1433 PubMed
129. Li T, Guo H, Li H, Jiang Y, Zhuang K, Lei C et al. MicroRNA-92a-1-5p increases CDX2 by targeting FOXD1 in bile acids-induced gastric intestinal metaplasia. Gut. 2019 doi:10.1136/gutjnl-2017-315318 PubMed
130. Chen C, Xu ZQ, Zong YP, Ou BC, Shen XH, Feng H et al. CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-kappaB pathway in colorectal cancer. Cell Death Dis. 2019 doi:10.1038/s41419-019-1431-6 PubMed
131. Hinata M, Kunita A, Abe H, Morishita Y, Sakuma K, Yamashita H, et al. Exosomes of Epstein-Barr virus-associated gastric carcinoma suppress dendritic cell maturation. Microorganisms. 2020;8:1776.10.3390/microorganisms8111776PMC769754233198173 doi:10.3390/microorganisms8111776 PubMed
132. Liu J, Wu S, Zheng X, Zheng P, Fu Y, Wu C et al. Immune suppressed tumor microenvironment by exosomes derived from gastric cancer cells via modulating immune functions. Sci Rep. 2020 doi:10.1038/s41598-020-71573-y PubMed
133. Yang E, Wang X, Gong Z, Yu M, Wu H, Zhang D. Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression. Signal Transduct Target Ther. 2020 doi:10.1038/s41392-020-00359-5 PubMed
134. Xu Z, Zeng S, Gong Z, Yan Y. Exosome-based immunotherapy: a promising approach for cancer treatment. Mol Cancer. 2020 doi:10.1186/s12943-020-01278-3 PubMed
135. Li X, Shao C, Shi Y, Han W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol. 2018 doi:10.1186/s13045-018-0578-4 PubMed
136. Fan Y, Liu Y, Qu X. ASO author reflections: the prognostic role of Exosomal PD-L1 in patients with gastric Cancer. Ann Surg Oncol. 2019 doi:10.1245/s10434-019-07864-0 PubMed
137. Fan Y, Che X, Qu J, Hou K, Wen T, Li Z et al. Exosomal PD-L1 retains immunosuppressive activity and is associated with gastric Cancer prognosis. Ann Surg Oncol. 2019 doi:10.1245/s10434-019-07431-7 PubMed
138. Zhang M, Fan Y, Che X, Hou K, Zhang C, Li C et al. 5-FU-induced Upregulation of Exosomal PD-L1 causes immunosuppression in advanced gastric Cancer patients. Front Oncol. 2020 doi:10.3389/fonc.2020.00492 PubMed
139. Yu W, Hurley J, Roberts D, Chakrabortty SK, Enderle D, Noerholm M, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol. 2021;32:466–77.10.1016/j.annonc.2021.01.074PMC826807633548389 doi:10.1016/j.annonc.2021.01.074 PubMed
140. Pan S, Zhang Y, Natalia A, Lim CZJ, Ho NRY, Chowbay B, et al. Extracellular vesicle drug occupancy enables real-time monitoring of targeted cancer therapy. Nat Nanotechnol. 2021.10.1038/s41565-021-00872-w33686255 doi:10.1038/s41565-021-00872-w PubMed
141. Zhou X, Zhu W, Li H, Wen W, Cheng W, Wang F et al. Diagnostic value of a plasma microRNA signature in gastric cancer: a microRNA expression analysis. Sci Rep. 2015 doi:10.1038/srep11251 PubMed
142. Dong Z, Sun X, Xu J, Han X, Xing Z, Wang D et al. Serum membrane type 1-matrix metalloproteinase (MT1-MMP) mRNA protected by Exosomes as a potential biomarker for gastric Cancer. Med Sci Monit. 2019 doi:10.12659/MSM.918486 PubMed
143. Huang Z, Zhu D, Wu L, He M, Zhou X, Zhang L et al. Six serum-based miRNAs as potential diagnostic biomarkers for gastric Cancer. Cancer Epidemiol Biomark Prev. 2017 doi:10.1158/1055-9965.EPI-16-0607 PubMed
144. Piao HY, Guo S, Wang Y, Zhang J. Exosomal Long non-coding RNA CEBPA-AS1 inhibits tumor apoptosis and functions as a non-invasive biomarker for diagnosis of gastric Cancer. Onco Targets Ther. 2020 doi:10.2147/OTT.S238706 PubMed
145. Zhao R, Zhang Y, Zhang X, Yang Y, Zheng X, Li X et al. Exosomal long noncoding RNA HOTTIP as potential novel diagnostic and prognostic biomarker test for gastric cancer. Mol Cancer. 2018 doi:10.1186/s12943-018-0817-x PubMed
146. Li S, Zhang M, Zhang H, Hu K, Cai C, Wang J et al. Exosomal long noncoding RNA lnc-GNAQ-6:1 may serve as a diagnostic marker for gastric cancer. Clin Chim Acta. 2020 doi:10.1016/j.cca.2019.10.047 PubMed
147. Wang J, Zhang H, Zhou X, Wang T, Zhang J, Zhu W et al. Five serum-based miRNAs were identified as potential diagnostic biomarkers in gastric cardia adenocarcinoma. Cancer Biomark. 2018 doi:10.3233/CBM-181258 PubMed
148. Li W, Gao YQ. MiR-217 is involved in the carcinogenesis of gastric cancer by down-regulating CDH1 expression. Kaohsiung J Med Sci. 2018 doi:10.1016/j.kjms.2018.02.003 PubMed
149. Lu X, Lu J, Wang S, Zhang Y, Ding Y, Shen X et al. Circulating serum exosomal miR-92a-3p as a novel biomarker for early diagnosis of gastric cancer. Future Oncol. 2021 doi:10.2217/fon-2020-0792 PubMed
150. Zheng GD, Xu ZY, Hu C, Lv H, Xie HX, Huang T et al. Exosomal miR-590-5p in serum as a biomarker for the diagnosis and prognosis of gastric Cancer. Front Mol Biosci. 2021 doi:10.3389/fmolb.2021.636566 PubMed
151. Cai C, Zhang H, Zhu Y, Zheng P, Xu Y, Sun J et al. Serum Exosomal Long noncoding RNA pcsk2-2:1 as a potential novel diagnostic biomarker for gastric Cancer. Onco Targets Ther. 2019 doi:10.2147/OTT.S229033 PubMed
152. Wang N, Wang L, Yang Y, Gong L, Xiao B, Liu X. A serum exosomal microRNA panel as a potential biomarker test for gastric cancer. Biochem Biophys Res Commun. 2017 doi:10.1016/j.bbrc.2017.10.003 PubMed
153. Li Q, Shao Y, Zhang X, Zheng T, Miao M, Qin L et al. Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer. Tumour Biol. 2015 doi:10.1007/s13277-014-2807-y PubMed
154. Yamamoto H, Watanabe Y, Oikawa R, Morita R, Yoshida Y, Maehata T et al. BARHL2 methylation using gastric wash DNA or gastric juice Exosomal DNA is a useful marker for early detection of gastric Cancer in an H. pylori-independent manner. Clin Transl Gastroenterol. 2016 doi:10.1038/ctg.2016.40 PubMed
155. Guo X, Lv X, Ru Y, Zhou F, Wang N, Xi H, et al. Circulating Exosomal gastric Cancer-associated Long noncoding RNA1 as a biomarker for early detection and monitoring progression of gastric Cancer: a multiphase study. JAMA Surg. 2020;155:572–9.10.1001/jamasurg.2020.1133PMC728794832520332 doi:10.1001/jamasurg.2020.1133 PubMed
156. Tang S, Cheng J, Yao Y, Lou C, Wang L, Huang X et al. Combination of four serum Exosomal MiRNAs as novel diagnostic biomarkers for early-stage gastric Cancer. Front Genet. 2020 doi:10.3389/fgene.2020.00237 PubMed
157. Shi Y, Wang Z, Zhu X, Chen L, Ma Y, Wang J et al. Exosomal miR-1246 in serum as a potential biomarker for early diagnosis of gastric cancer. Int J Clin Oncol. 2020 doi:10.1007/s10147-019-01532-9 PubMed
158. Shao Y, Tao X, Lu R, Zhang H, Ge J, Xiao B et al. Hsa_circ_0065149 is an Indicator for early gastric Cancer screening and prognosis prediction. Pathol Oncol Res. 2020 doi:10.1007/s12253-019-00716-y PubMed
159. Lin LY, Yang L, Zeng Q, Wang L, Chen ML, Zhao ZH et al. Tumor-originated exosomal lncUEGC1 as a circulating biomarker for early-stage gastric cancer. Mol Cancer. 2018 doi:10.1186/s12943-018-0834-9 PubMed
160. Zhang Y, Han T, Feng D, Li J, Wu M, Peng X et al. Screening of non-invasive miRNA biomarker candidates for metastasis of gastric cancer by small RNA sequencing of plasma exosomes. Carcinogenesis. 2020 doi:10.1093/carcin/bgz186 PubMed
161. Yun J, Han SB, Kim HJ, Go SI, Lee WS, Bae WK et al. Exosomal miR-181b-5p Downregulation in ascites serves as a potential diagnostic biomarker for gastric Cancer-associated malignant ascites. J Gastric Cancer. 2019 doi:10.5230/jgc.2019.19.e27 PubMed
162. Kumata Y, Iinuma H, Suzuki Y, Tsukahara D, Midorikawa H, Igarashi Y et al. Exosomeencapsulated microRNA23b as a minimally invasive liquid biomarker for the prediction of recurrence and prognosis of gastric cancer patients in each tumor stage. Oncol Rep. 2018 doi:10.3892/or.2018.6418 PubMed
163. Tang W, Fu K, Sun H, Rong D, Wang H, Cao H. CircRNA microarray profiling identifies a novel circulating biomarker for detection of gastric cancer. Mol Cancer. 2018 doi:10.1186/s12943-018-0888-8 PubMed
164. Zheng P, Zhang H, Gao H, Sun J, Li J, Zhang X et al. Plasma Exosomal Long noncoding RNA lnc-SLC2A12-10:1 as a novel diagnostic biomarker for gastric Cancer. Onco Targets Ther. 2020 doi:10.2147/OTT.S253600 PubMed
165. Xu H, Zhou J, Tang J, Min X, Yi T, Zhao J et al. Identification of serum exosomal lncRNA MIAT as a novel diagnostic and prognostic biomarker for gastric cancer. J Clin Lab Anal. 2020 doi:10.1002/jcla.23323 PubMed
166. Tao X, Shao Y, Lu R, Ye Q, Xiao B, Ye G et al. Clinical significance of hsa_circ_0000419 in gastric cancer screening and prognosis estimation. Pathol Res Pract. 2020 doi:10.1016/j.prp.2019.152763 PubMed
167. Liu X, Chu KM. Exosomal miRNAs as circulating biomarkers for prediction of development of haematogenous metastasis after surgery for stage II/III gastric cancer. J Cell Mol Med. 2020 doi:10.1111/jcmm.15253 PubMed
168. Ohzawa H, Kumagai Y, Yamaguchi H, Miyato H, Sakuma Y, Horie H et al. Exosomal microRNA in peritoneal fluid as a biomarker of peritoneal metastases from gastric cancer. Ann Gastroenterol Surg. 2020 doi:10.1002/ags3.12296 PubMed
169. Ding XQ, Wang ZY, Xia D, Wang RX, Pan XR, Tong JH. Proteomic profiling of serum Exosomes from patients with metastatic gastric Cancer. Front Oncol. 2020 doi:10.3389/fonc.2020.01113 PubMed
170. Chanteloup G, Cordonnier M, Isambert N, Bertaut A, Hervieu A, Hennequin A et al. Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot study. J Extracell Vesicles. 2020 doi:10.1080/20013078.2020.1766192 PubMed
171. Keerthikumar S, Chisanga D, Ariyaratne D, Al Saffar H, Anand S, Zhao K et al. ExoCarta: a web-based compendium of Exosomal cargo. J Mol Biol. 2016 doi:10.1016/j.jmb.2015.09.019 PubMed
172. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015 doi:10.1038/nbt.3330 PubMed
173. Guan XW, Zhao F, Wang JY, Wang HY, Ge SH, Wang X et al. Tumor microenvironment interruption: a novel anti-cancer mechanism of proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes. Am J Cancer Res. 2017 PubMed
174. Qiao L, Hu S, Huang K, Su T, Li Z, Vandergriff A et al. Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs. Theranostics. 2020 doi:10.7150/thno.39434 PubMed
175. Geng T, Pan P, Leung E, Chen Q, Chamley L, Wu Z. Recent advancement and technical challenges in developing small extracellular vesicles for Cancer drug delivery. Pharm Res. 2021 doi:10.1007/s11095-021-02988-z PubMed
176. Cabeza L, Perazzoli G, Pena M, Cepero A, Luque C, Melguizo C et al. Cancer therapy based on extracellular vesicles as drug delivery vehicles. J Control Release. 2020 doi:10.1016/j.jconrel.2020.08.018 PubMed
177. Dai J, Su Y, Zhong S, Cong L, Liu B, Yang J et al. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct Target Ther. 2020 doi:10.1038/s41392-020-00261-0 PubMed
178. Shehzad A, Islam SU, Shahzad R, Khan S, Lee YS. Extracellular vesicles in cancer diagnostics and therapeutics. Pharmacol Ther. 2021 doi:10.1016/j.pharmthera.2021.107806 PubMed
179. Chen W, Jiang J, Xia W, Huang J. Tumor-related Exosomes contribute to tumor-promoting microenvironment: an immunological perspective. J Immunol Res. 2017 doi:10.1155/2017/1073947 PubMed
180. Whiteside TL. Exosomes and tumor-mediated immune suppression. J Clin Invest. 2016 doi:10.1172/JCI81136 PubMed
181. Olejarz W, Dominiak A, Zolnierzak A, Kubiak-Tomaszewska G, Lorenc T. Tumor-derived Exosomes in immunosuppression and immunotherapy. J Immunol Res. 2020 doi:10.1155/2020/6272498 PubMed
182. Andre F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol. 2004 doi:10.4049/jimmunol.172.4.2126 PubMed
183. Cheng L, Wang Y, Huang L. Exosomes from M1-polarized macrophages potentiate the Cancer vaccine by creating a pro-inflammatory microenvironment in the lymph node. Mol Ther. 2017 doi:10.1016/j.ymthe.2017.02.007 PubMed
184. Wiklander OP, Nordin JZ, O'Loughlin A, Gustafsson Y, Corso G, Mager I et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles. 2015 doi:10.3402/jev.v4.26316 PubMed
185. Jayasinghe MK, Tan M, Peng B, Yang Y, Sethi G, Pirisinu M, et al. New approaches in extracellular vesicle engineering for improving the efficacy of anti-cancer therapies. Semin Cancer Biol. 2021.10.1016/j.semcancer.2021.02.01033609665 doi:10.1016/j.semcancer.2021.02.010 PubMed
186. Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics. 2021 doi:10.7150/thno.52570 PubMed
187. Zhang X, Zhang H, Gu J, Zhang J, Shi H, Qian H, et al. Engineered extracellular vesicles for Cancer therapy. Adv Mater. 2021;33:e2005709.10.1002/adma.20200570933644908 doi:10.1002/adma.202005709 PubMed
188. Elsharkasy OM, Nordin JZ, Hagey DW, de Jong OG, Schiffelers RM, Andaloussi SE et al. Extracellular vesicles as drug delivery systems: why and how?. Adv Drug Deliv Rev. 2020 doi:10.1016/j.addr.2020.04.004 PubMed
189. Pham TC, Jayasinghe MK, Pham TT, Yang Y, Wei L, Usman WM et al. Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery. J Extracell Vesicles. 2021 doi:10.1002/jev2.12057 PubMed
190. Wang J, Li W, Zhang L, Ban L, Chen P, Du W et al. Chemically edited Exosomes with dual ligand purified by microfluidic device for active targeted drug delivery to tumor cells. ACS Appl Mater Interfaces. 2017 doi:10.1021/acsami.7b06464 PubMed
191. Nasiri Kenari A, Cheng L, Hill AF. Methods for loading therapeutics into extracellular vesicles and generating extracellular vesicles mimetic-nanovesicles. Methods. 2020 doi:10.1016/j.ymeth.2020.01.001 PubMed
192. Pan S, Pei L, Zhang A, Zhang Y, Zhang C, Huang M et al. Passion fruit-like exosome-PMA/au-BSA@Ce6 nanovehicles for real-time fluorescence imaging and enhanced targeted photodynamic therapy with deep penetration and superior retention behavior in tumor. Biomaterials. 2020 doi:10.1016/j.biomaterials.2019.119606 PubMed
193. Kim S, Sohn HJ, Lee HJ, Sohn DH, Hyun SJ, Cho HI et al. Use of engineered Exosomes expressing HLA and Costimulatory molecules to generate antigen-specific CD8+ T cells for adoptive cell therapy. J Immunother. 2017 doi:10.1097/CJI.0000000000000151 PubMed
194. Nguyen VVT, Witwer KW, Verhaar MC, Strunk D, van Balkom BWM. Functional assays to assess the therapeutic potential of extracellular vesicles. J Extracell Vesicles. 2020 doi:10.1002/jev2.12033 PubMed